Telecommunication Technology-based Online Survey

NCT06159699 | Recruiting DMC

• 1 other identifier: CRI-248
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics will be assessed. The continuous depersonalized online survey is performed using the original informational resources in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation.

Conditions

Risk Factors; Polypharmacy; Drug Interactions; Self Medication; COVID-19

Keywords

Polypharmacy; Potential Drug-Drug Interactions; Self Medication; COVID-19; Medical Imaging; Environmental Risk Factors; Protracted Low-Dose-Rate Radiation Exposure

Outcome Measures

Primary Outcomes (2)

• Incidence of serious drug-drug interactions (percent)

  Incidence of serious drug-drug interactions (DDIs) is assessed as a percentage (%) of completed survey questionnaires associated with serious DDIs relative to the size of respondent population.

  Five years

• Median number of serious drug-drug interactions (n)

  Median number of serious drug-drug interactions is assessed per one completed survey questionnaire containing information on pharmacotherapy.

  Five years

Secondary Outcomes (12)

• Incidence of polypharmacy (percent)

  Five years

• Incidence of MRI administration (percent)

  Two years

• Incidence of CT administration (percent)

  Two years

• Incidence of diagnostic ultrasound administration (percent)

  Two years

• Incidence of diagnostic X-ray administration (percent)

  Two years

Study Arms (1)

Non-structured population

The respondent will represent the non-structured population of the Russian Federation invited to participate in the study using the SMS-Target tool provided by OOO T2 Mobile Company.

Other: Online Survey; Diagnostic Test: Genetic Testing

Interventions

Online Survey OTHER

The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.

Also known as: Telecommunication-Based Survey

Non-structured population

Genetic Testing DIAGNOSTIC_TEST

Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.

Also known as: Genetic Polymorphisms of Drug-Metabolizing Enzymes

Non-structured population

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Nonstructured population aged 18 years and older willing to complete the entire questionnaire and signing the informed concent form.

You may qualify if:

• age of 18 years and older
• signing the informed concent form online
• completion of the entire questionnaire

You may not qualify if:

• age under 18 years
• refuse to sign the informed concent form

Sponsors & Collaborators

• Tomsk National Research Medical Center of the Russian Academy of Sciences: lead

Study Sites (1)

Tomsk National Research Medical Center, Russian Academy of Sciences

Tomsk, 634012, Russia

RECRUITING

MeSH Terms

Conditions

COVID-19

Interventions

Genetic Testing

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Genetic Techniques; Genetic Services; Health Services; Health Care Facilities Workforce and Services; Diagnostic Services; Preventive Health Services

Study Officials

• Nina D Anfinogenova, PhD

  Tomsk NRMC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nina D Anfinogenova, PhD

CONTACT

+73822554111; anfiyj@gmail.com

Study Design

• Study Type: observational
• Observational Model: ECOLOGIC OR COMMUNITY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 28, 2023
• First Posted: December 7, 2023
• Study Start: December 2, 2022
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: January 27, 2026

Record last verified: 2026-01

Locations

RU (1)